The PROPEL family of implants offers 3 steroid-eluting implants under one brand, allowing ENTs to select the best option that conforms to the anatomical needs of their patients1-3
For ethmoid sinus1
For ethmoid sinus and
frontal sinus opening2
For sinus ostia:
frontal and maxillary3
Learn more about the benefits of PROPEL implants after sinus surgery
PROPEL is the FIRST and ONLY PMA-approved steroid-eluting sinus implant4
OPENS + DELIVERS
PROPEL keeps the sinuses open while releasing MF
PROPEL implants feature an innovative
Self-expanding design that opens and supports the sinus cavity1
Non-obstructive design allows for sinus mucociliary clearance and the delivery of topical rinses1
Dissolvable frame bio-absorbs over 30-45 days after placement as the sinus cavity heals11
Delivers 370 μg of MF over 30 days*
MF present in the sinus mucosal tissue for up to 60 days5*
*Pre-clinical animal data.
|Dexamethasone||Very Low (<1.0)9||Very Low (100)||High (76%)|
|Triamcinolone (Kenalog)||Low (1.0)||Low (233)||Medium (46%)|
|Budesonide||Low (1.6)||Intermediate (935)||Medium (34%)|
|Mometasone furoate||High (20.0)||High (2300)||Very Low (<1%)|
*Lipophilicity numbers normalized relative to triamcinolone acetonide.
†As measured by relative receptor binding affinity compared to dexamethasone, which is set to a value of 100. Higher values designate greater potency.
‡As measured by plasma concentration of drug from intranasal vs. intravenous route.
Mometasone furoate was selected for use in PROPEL implants for its optimal sinonasal drug characteristics10:
Readily absorbs into tissue
Targeted and potent
High glucocorticoid receptor affinity
Low systemic bioavailability
Minimizes systemic effects
PROPEL implants are clinically proven to maintain patency and improve patient outcomes following ESS by targeting inflammation, the underlying cause of chronic rhinosinusitis
This site is intended for healthcare professionals in the United States